571 related articles for article (PubMed ID: 24436152)
1. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
2. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
3. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
4. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
5. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
6. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
7. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
Maese L; Loh ML; Choi MR; Lin T; Aoki E; Zanette M; Agarwal S; Iannone R; Silverman JA; Silverman LB; Raetz EA; Rau RE
Blood; 2023 Feb; 141(7):704-712. PubMed ID: 36108304
[TBL] [Abstract][Full Text] [Related]
10. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
11. Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients.
Gossai N; Richards M; Boman L; Messinger Y; Gernbacher S; Perkins J; Bostrom B
J Pediatr Hematol Oncol; 2018 May; 40(4):312-315. PubMed ID: 29334534
[TBL] [Abstract][Full Text] [Related]
12. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
13. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
Lin T; Hernandez-Illas M; Rey A; Jenkins J; Chandula R; Silverman JA; Choi MR
Clin Transl Sci; 2021 May; 14(3):870-879. PubMed ID: 33278328
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
16. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Billett AL; Carls A; Gelber RD; Sallan SE
Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
[TBL] [Abstract][Full Text] [Related]
17. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
18. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
Sandley M; Angus J
Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
[TBL] [Abstract][Full Text] [Related]
19. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia.
Lin T; Whigham T; Fernando I; Choi MR; Wang Q; Silverman JA
Clin Transl Sci; 2023 May; 16(5):898-909. PubMed ID: 36929533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]